Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24011297 | 0.86 | EPHX1 (0.55) | EPHX1MEN1KMT2ATP53RAB9A | |
| SCHEMBL24011523 | 0.85 | EPHX1 (0.67) | EPHX1MEN1KMT2ATP53RAB9A | |
| SCHEMBL24011160 | 0.84 | EPHX1 (0.69) | EPHX1MEN1KMT2ATP53RAB9A | |
| SCHEMBL24011131 | 0.83 | EPHX1 (0.72) | EPHX1MEN1KMT2ATP53RAB9A | |
| SCHEMBL24011130 | 0.82 | EPHX1 (0.71) | EPHX1MEN1KMT2ATP53RAB9A | |
| SCHEMBL24011289 | 0.82 | EPHX1 (0.71) | EPHX1MEN1KMT2ATP53RAB9A | |
| SCHEMBL26777135 | 0.81 | EPHX1 (0.69) | EPHX1MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL24011283 | 0.79 | EPHX1 (0.74) | EPHX1MEN1KMT2ATP53RAB9A | |
| SCHEMBL24011508 | 0.79 | EPHX1 (0.74) | EPHX1MEN1KMT2ATP53RAB9A | |
| SCHEMBL12196171 | 0.79 | EPHX1 (1.00) | EPHX1MEN1KMT2ATP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2021226276-A2 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | EPHX1 3913/4885MEN1 110/4885KMT2A 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.